Leveragen Strengthens Singularity Platform IP with Australian Patent Grant

Leveragen, Inc., a Boston-based biotechnology company advancing in vivo antibody discovery, today announced the grant of Australian Patent No. 2022271276...

September 10, 2026 | Thursday | News
Windward Bio Reports Positive Phase 2 Results for Twice-Yearly WIN378 in Asthma

The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients...

September 10, 2026 | Thursday | News
Intellia Therapeutics’ Lonvo-z Wins FDA Priority Review for One-Time HAE Treatment

FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027 Positions lonvo-z to be the world’s first in vivo CRISPR-based therapy an...

September 10, 2026 | Thursday | News
Bone Biologics Expands NB1 Spine Fusion Trial to Six Australian Hospital Sites

Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for s...

September 10, 2026 | Thursday | News
HCW Biologics Signs Exclusive Distribution Agreement with Akron Biotech for HCW11-006

Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagen...

September 10, 2026 | Thursday | News
Aptar Pharma Partners with Aceso Therapeutics to Advance Inhaled ASO for Cystic Fibrosis

-Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced a collaboration with Aceso Therapeutics, a...

September 09, 2026 | Wednesday | News
Novartis’ Del-Desiran Misses Phase III HARBOR Primary Endpoint in DM1

HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options ...

September 09, 2026 | Wednesday | News
Rezubio Advances RZ-520 Into Phase 1 Clinical Trial

Rezubio announced that it has successfully completed dosing of the first cohort in its Phase 1 clinical trial following clearances from the US FDA a...

September 08, 2026 | Tuesday | News
Novartis Pelacarsen Phase III Trial Fails to Reduce Cardiovascular Events

Novartis announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of red...

September 08, 2026 | Tuesday | News
Thryv Therapeutics Licenses Novel SGK1 Inhibitor Platform to Expand Into Neurodegenerative Diseases

Thryv Therapeutics Inc. ("Thryv"), a clinical-stage biopharmaceutical company advancing selective SGK1 inhibitors, announced that it has entered into an ...

September 07, 2026 | Monday | News
Mabwell Reports Positive Phase Ib/IIa Results for Anti-ST2 Antibody 9MW1911 in COPD

Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced the Phase Ib/IIa clinical results of its anti-S...

September 07, 2026 | Monday | News
AtomVie Opens $160 Million Radiopharmaceutical Manufacturing Facility in Ontario

AtomVie Global Radiopharma (AtomVie), a leading global Contract Development and Manufacturing Organization (CDMO) in the radiopharmaceutical industry, ce...

September 07, 2026 | Monday | News
Resonant Clinical Solutions Acquires Creapharm Bioservices to Expand European Biorepository Capabilities

Resonant Clinical Solutions, a global clinical solutions partner serving life sciences organizations across the clinical supply chain and sample lifecycl...

September 07, 2026 | Monday | News
HCW Biologics Secures U.S. Patent Allowance for HCW9302 in Alopecia Areata

HCW Biologics Inc. (the “Company” or “HCW Biologics”), a U.S.-based clinical-stage biopharmaceutical company focused on developin...

September 04, 2026 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close